New treatment using engineered NK cells for ovarian cancer
Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer
This study is testing a new treatment for ovarian cancer that uses specially modified immune cells to better fight the disease, especially for patients whose cancer hasn't responded to standard therapies, with the hope of providing a safer and more effective option.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10931359 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunotherapy using engineered natural killer (NK) cells to treat ovarian cancer, particularly targeting patients with platinum-resistant forms of the disease. The approach involves modifying NK cells to enhance their ability to recognize and kill cancer cells, while also improving their persistence in the body. By utilizing a specific target called TROP2, the study aims to create a more effective and safer treatment option compared to traditional therapies. Patients may benefit from this innovative therapy that seeks to overcome the limitations of current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with platinum-resistant ovarian cancer who are seeking new treatment options.
Not a fit: Patients with early-stage ovarian cancer or those who have not undergone platinum-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with ovarian cancer, particularly those who have not responded to existing therapies.
How similar studies have performed: Previous studies have shown promising results with engineered NK cell therapies in other malignancies, indicating potential for success in this novel application.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Rezvani, Katy — University of Tx Md Anderson Can Ctr
- Study coordinator: Rezvani, Katy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.